Serum lipoprotein(a), and plasminogen activator inhibitor-1 in uncomplicated type 2 diabetes mellitus: a case–control study
Open Access
- 3 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (8) , 3801-3805
Abstract
Background: Increased levels of lipoprotein (a) [Lp(a)] are indicative of coronary artery disease (CAD). Dyslipidemia, which is an established risk factor for CAD, is also an additional adverse effect of uncontrolled type 2 diabetes. Procoagulant and fibrinolytic indicators have been linked to the development of type 2 diabetes. Plasminogen activator inhibitor-1 (PAI-1), plays a significant negative regulatory role in fibrinolysis, through its function as the main inhibitor of tissue plasminogen activator. This study was designed to investigate the levels of Lp(a) and PAI-1 in uncomplicated type 2 diabetic patients and their association with healthy controls. Materials and methods: A case–control study designed for the estimation of Lp(a) and PAI-1 in serum after collecting blood samples from type 2 diabetic patients at the Layla Qasim Diabetic Center in Erbil, Iraq. The study included 90 participants, of whom 30 were healthy controls (15 males and 15 females). The remaining 60 cases were patients with type 2 diabetes with a duration of up to 6 years (30 males and 30 females). Results: Serum Lp(a) and PAI-1 levels were significantly lower in type 2 diabetic patients than in controls (P<0.01), this is an opposite result that usually happen in uncontrolled and complicated diabetic patients. Conclusions: The results were clearly stated a beneficial effect of Metformin on the levels of Lp(a) and PAI-1 in type 2 diabetes, so lowering their concentrations would help prevention of CAD, a known cause of death in diabetic patients.Keywords
This publication has 29 references indexed in Scilit:
- The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitusJournal of Physiology and Pathophysiology, 2013
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part IEuropean Heart Journal, 2013
- PAI-1 and Diabetes: A Journey From the Bench to the BedsideDiabetes Care, 2012
- Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular DiseaseJACC, 2012
- Lipoprotein(a)Current Opinion in Lipidology, 2012
- Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based surveyCardiovascular Diabetology, 2011
- Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjectsCardiovascular Diabetology, 2011
- Review article: Coagulation and fibrinolysis in diabetesDiabetes & Vascular Disease Research, 2010
- Cardiovascular Disease in Type 2 Diabetes From Population to Man to MechanismsDiabetes Care, 2010
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009